entertainment -WSS

entertainment

author：Wikipedia 2025-09-29 18:17:35 - browse：734

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter:

Novo Nordiskis conducting a large clinical trial to prove that its GLP-1 drug Wegovy, in addition to helping people lose weight, also improves cardiovascular health. The SELECT study enrolled 17,500 participants who had overweight or obesity and had preexisting heart disease. The participants were then randomized to receive weekly injections of Wegovy or a matching placebo. The primary goal is to determine the extent to which Wegovy reduces the risk of heart attacks, strokes, and heart-related deaths. Wegovy is already a blockbuster drug based on weight loss alone, but proving an additional cardiovascular benefit could open the commercial floodgates.

BridgeBiowill report in July an analysis of all-cause mortality from a clinical trial of its heart drug acoramidis. The outcome is an important, second attempt at demonstrating benefit for acoramidis in a progressive heart disease called ATTR-CM. In December 2021, the drug performed no better than a placebo on a test of how far study participants could walk over the course of six minutes, failing to achieve its primary goal. But in this second part of the same study, BridgeBio will determine if acoramidis can significantly reduce hospitalizations and death over the course of 30 months.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： House looks to weaken Medicare negotiation

leisure time

WSS

Colorectal cancer study finds potential in overlooked immune cell

Change Healthcare cyberattack outage could last weeks

An inside look at PIPEs, biotech's buzzy new financing tool

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

AI can decode, harness the power of the humane immune system

Change Healthcare cyberattack outage could last weeks

Wikipedia

entertainment

entertainment

23andMe had bad news about my health. I wish a person had delivered it

Sana to lay off nearly a third of staff, de

New air purifier tech could be key to improving indoor air quality

Biotech companies concerned about China biosecurity crackdown

Cancer drug shortages should be causing more outrage

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

How one medical school became remarkably diverse

Why Charlie Gard's case is so disturbing to Americans

The high cost of giving birth even with insurance

FogPharma raises $145 million in rare Series E round

focus

House looks to weaken Medicare negotiation

Phenylephrine and the overlooked value of the placebo effect

What to expect at HLTH 2023, the health care industry conference

Senate panel eyes new effort on drug shortages

Clinical trials giant ICON acquires HumanFirst

When women are denied an abortion, their children fare worse than peers

leisure time

hotspot

focus

explore